Susceptibilities of 28 strains of Pseudomonas aeruginosa, 32 strains of Enterobacteriaceae and 24 strains of Staphylococcus aureus were tested against combinations of enoxacin with either cefsulodin, piperacillin, or amikacin, enoxacin with either aztreonam, latamoxef or amikacin, and enoxacin with either oxacillin, clindamycin or vancomycin, respectively. Synergy was detected by the agar dilution technique and was defined as a four-fold decrease in the inhibitory concentration of both drugs (SFIC <0-5). Against Ps. aeruginosa, synergy occurred in 28-5% of the strains for enoxacin plus cefsulodin, 17-6% for enoxacin plus piperacillin, and 3-7% for enoxacin plus amikacin. Against the Enterobacteriaceae, synergy was detected with enoxacin plus aztreonam, latamoxef or amikacin in 9-3%, 3-1% and 0% of strains, respectively. Against Staph. aureus, no synergy was demonstrable with enoxacin plus oxacillin, clindamycin or vancomycin. No antagonism was detected for any combination tested. Selected strains demonstrating synergy by the agar dilution method for enoxacin plus cefsulodin or piperacillin failed to show synergy in kinetic studies.
Introduction
Enoxacin is a new oral quinolone carboxylic acid compound which inhibits DNA gyrase activity preventing supercoiling of DNA. Many strains of bacteria resistant to other antibacterial agents have been shown to be susceptible to enoxacin (Bassey et al., 1984; Wise, Andrews & Danks, 1984) . Treatment of infections caused by bacteria resistant to available antimicrobial agents can be difficult and frequently requires the administration of parenteral antibiotics in combination. Because of lack of published data on the effect of enoxacin in combination with other antibiotics, this in-vitro study was undertaken to examine the activity of enoxacin in combination with /Mactams and aminoglycosides against Pseudomonas aeruginosa and the Enterobacteriaceae, and in combination with clindamycin, vancomycin and oxacillin against Staphylococcus aureus.
Materials and methods
The following antibiotics were used: amikacin and oxacillin (Bristol Laboratories, Syracuse, New York), aztreonam (E. R. Squibb & Sons, Princeton, New Jersey), Clinical isolates were obtained from two large Albany hospitals. The number, distribution, and antibiotic susceptibility of the 84 strains are shown in Table I .
Agar dilution MICs were determined by the method of Washington & Sutter (1980) , and an inoculum of 10 4 cfu/spot. The MIC was defined as the lowest concentration of antibiotic at which complete inhibition of growth occurred (a fine haze or single colony was disregarded). The MICs (mg/1) to enoxacin of the ATCC control strains were: 
Enterobacteriaceae"
Staph. aureus 66-7 58-5 80-7 >20 Antagonism 00 00 00 00 00 00 00 00 00 "Number and strains described in Table I . Synergy was determined by the agar dilution method utilizing a chequerboard doubling dilution technique. The inoculum was again 10* cfu/spot. For selected strains timed kill curves were observed. Following overnight growth in Mueller-Hinton broth, an inoculum of 5 x 10 5 cfu/ml was added to the broth containing antibiotic equivalent to 1/4 of the MIC of each drug. After aerobic incubation at 37°C for 0, 1, 2, 3, 4, 6 and 24 h, 0-1 ml samples were spread on Mueller-Hinton agar. Plates were incubated aerobically at 37°C for 20 h and the colonies were counted with an electronic colony counter.
The fractional inhibitory concentration or FIC (MIC in combination/MIC alone) for each component as well as the sum of FICs (ZFIC) for each chequerboard combination was calculated (Hallender et ah, 1982) . The observed synergy, additive effects, indifference and antagonism are shown in Table II . For the timed kill curves, synergy was defined as ^21og 10 decreases in cfu/ml between the drug combination and its most active constituent at 24 h. Table I , enoxacin was more active against Ps. aeruginosa than cefsulodin, piperacillin or amikacin. Against the Enterobacteriaceae, enoxacin had similar or greater activity than aztreonam, latamoxef or amikacin. Against Staph. aureus, the activity of enoxacin was similar to or less than oxacillin, clindamycin or vancomycin.
Results

As demonstrated in
In combination (Table II) enoxacin demonstrated greatest synergy with cefulsodin (28-5%), followed by piperacillin (17-6%) against Ps. aeruginosa. Against the Enterobacteriaceae, synergy was less marked with enoxacin plus aztreonam (9-3%) and enoxacin plus latamoxef (3-1%). Only a single strain of Ps. aeruginosa showed synergy with enoxacin plus amikacin while against the Enterobacteriaceae there was none. None of the Staph. aureus strains showed synergy with enoxacin plus oxacillin, clindamycin, or vancomycin. In general an additive effect was observed when testing Ps. aeruginosa, and an additive effect or indifference was observed with the Enterobacteriaceae and Staph. aureus. There was no antagonism for any combination tested.
Timed kill curves were used to detect synergy with enoxacin and /Mactams for four strains of Ps. aeruginosa resistant to amikacin (MIC ^ 32 mg/1). Three strains demonstrated synergy by the agar dilution technique with enoxacin plus cefsulodin, and one showed an additive effect with enoxacin plus cefsulodin or enoxacin plus piperacillin. None of these strains demonstrated synergy by the timed kill curve technique.
Discussion
In this in-vitro study we demonstrated that enoxacin in combination with eight other antimicrobial agents showed no evidence of antagonism against three groups of clinical bacterial strains and that synergy by the agar dilution technique occurred in 3-28% of the strains. Synergy was most frequently observed with enoxacin plus cefsulodin against Ps. aeruginosa (28-5%). Synergy was less common with enoxacin and other antimicrobials tested against Ps. aeruginosa or the Enterobacteriaceae. Synergy was not demonstrable for enoxacin in combination with any of the antistaphylococcal drugs tested. Either an additive effect or indifference was observed with combinations of enoxacin plus other antimicrobial agents. These data are in contrast to the considerably greater rates of synergy observed in testing combinations of /Mactams plus aminoglycosides against Gram-negative bacteria (Baltch & Smith, 1985) . Our data are similar to those of Haller (1985) who demonstrated poor or no synergy with enoxacin plus amikacin and who also detected no synergy with combinations of ciprofloxacin plus aminoglycoside against strains of Ps. aeruginosa and Enterobacteriaceae.
To date we are unaware of other publications describing the effect of enoxacin in combination with other classes of antibacterial agents. We have demonstrated that antagonism is absent when enoxacin is tested in combination, and that selected bacterial strains may show synergy, especially when tested in combination with cefsulodin against Ps. aeruginosa. This lack of antagonism with other antimicrobials could be beneficial in clinical states where resistant micro-organisms are present or where broad cover against infecting strains is desired.
